ORGS | Orgenesis Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.9500 - 1.0400
52 Week Range	0.8700 - 10.80
Beta	1.32
Implied Volatility	587.73%
IV Rank	100.00%
Day's Volume	2,639
Average Volume	34,338
Shares Outstanding	5,169,250
Market Cap	4,910,788
Sector	Healthcare
Industry	Biotechnology
IPO Date	2012-03-13

Valuation
Profitability
Growth
Health
P/E Ratio	-0.04
Forward P/E Ratio	N/A
EPS	-24.46
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	146
Country	USA
Website	ORGS

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

ORGS's peers: TFFP

*Chart delayed

Analyzing fundamentals for ORGS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see ORGS Fundamentals page.

Watching at ORGS technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on ORGS Technicals page.